Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4142 - 4142

Published: Dec. 12, 2024

Background: The lengthening of the lifespan led to an increase in breast cancer (BC) diagnosed very old age, but treatment recommendations this patient group usually lack evidence-based practice. We conducted a prospective observational monocentric study specifically targeting patients with invasive BC at 80 years age or older. Methods: enrolled 88 consecutively observed for new diagnosis aim was investigate progression-free (PFS) and overall survival (OS), long follow-up period, along clinico-pathological characteristics population. Results: At end 5-year follow-up, estimated OS PFS probabilities were 82.9% (95% CI: 71.3–95.3%) 64.0% 51.7–79.2%), respectively. After 8.5 from diagnosis, 48.9% died. cause death 32.6% patients, different 13.9%, unknown remaining. Surgery performed 69.3% cases associated improved 12-month (p < 0.001). Adjuvant systemic therapy radiotherapy omitted 32% 93% eligible A higher rate metastatic disease comparison data described younger people, as well significantly high drop-out (27.3%). Conclusions: Ultra-old have not negligible life expectancy; therefore, oncologic should be optimal adequately fight BC, always considering quality these frail patients. Future research focus on developing personalized protocols that incorporate comprehensive geriatric assessments quality-of-life metrics. Additionally, larger, multicentric studies are needed validate our findings explore role emerging therapies group.

Language: Английский